Group 1 - The company Nanjing Pharmaceutical is under investigation by the China Securities Regulatory Commission (CSRC) for suspected violations in annual report information disclosure, leading to a significant drop in stock price and investor losses [1] - The CSRC's investigation is linked to the company's early recognition of revenue amounting to 24.54 million yuan in December 2023, which was later corrected as an accounting error, potentially being a key reason for the investigation [1] - The company has restated its financial reports, reducing its 2023 revenue by 24.54 million yuan, which represents 3.4% of the total revenue for that year, impacting investor decision-making [1] Group 2 - Investors who purchased shares before September 30, 2025, and sold or held them at a loss after October 1, 2025, are eligible to participate in compensation claims through legal channels [2] - The urgency for affected investors to engage in legal action is emphasized, as the company faces significant challenges [2]